Ovation.io, a leader in research-focused genomic data solutions, has unveiled a first-of-its-kind dataset combining whole genome sequencing (WGS) data with longitudinal clinical records from patients treated with GLP-1 receptor agonists. This initiative aims to include 8,500 patient records by the end of 2025, creating an invaluable resource for precision medicine research in metabolic diseases.
In a major milestone, a global top 10 biopharmaceutical company has committed to a three-year data license, becoming the first to leverage this dataset for drug discovery and biomarker research.
The dataset includes:
✅ High-Quality WGS Data: Enabling analysis of genetic variations that influence drug efficacy, metabolism, and safety.
✅ Longitudinal Clinical Records: Tracking real-world treatment responses, dosing, weight loss, glucose control, and adverse events.
✅ Diverse Patient Cohorts: Ensuring broad demographic representation for generalizable insights and sub-population analytics.
“By linking genomic and clinical data at scale, we empower researchers to uncover biomarkers of treatment response and develop predictive tools for patient stratification,” said Curt Medeiros, CEO of Ovation.io.
GLP-1 receptor agonists, including semaglutide and liraglutide, have transformed the treatment of type 2 diabetes and obesity, yet patient responses vary significantly. Ovation’s dataset bridges the gap between genomics and clinical outcomes, supporting precision medicine advancements.
The dataset is available for direct delivery or via research platforms, inviting collaboration from academic institutions, pharmaceutical companies, and clinical researchers.
Ovation.io is dedicated to unlocking the power of genomic data at scale to accelerate precision medicine development. Through its cloud-based LIMS and Ovation Research Network, the company supports clinical laboratories in adopting advanced molecular tests and contributing to research.